Cristal Therapeutics
PrivateLast Round
Grant
Jul 2, 2020
Total Funding Raised
$24.08M
Company Overview
Cristal Therapeutics operates in Healthcare & Life Sciences and is based in Maastricht. Its latest recorded funding round was a Grant round in July 2020.
Cristal Therapeutics is a biotechnology company that develops nanomedicines and bioconjugation technologies designed to improve targeted therapy for cancer and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cristal Therapeutics Comparables
Compare Cristal Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NaDeNo Nanoscience | 83% | |
| SNC Therapeutics, Inc. | 82% | |
| Centrose | 77% |
For institutional investors. Book with your work email.
Cristal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 2, 2020 | ||||
| Grant | Nov 28, 2017 | ||||
| Series B | Jan 19, 2017 | ||||
| Series A | Dec 15, 2014 | ||||
| Seed | Jul 1, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cristal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brabantse Ontwikkelings Maatschappij | Series B |
| European Commission (Horizon Europe) | Grant |
| European Commission | Grant |
| Thuja Capital | Series A, Seed |
| Brightlands Venture Partners | Series B, Series A |
| LIOF | Series B, Seed |
| BioGeneration Ventures | Series B, Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 26, 2025
Partnered with Curapath to expand CliCr(R) platform.
For institutional investors. Book with your work email.
Cristal Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cristal Therapeutics's valuation, stock price, and market status.
Is Cristal Therapeutics a public or private company?
Cristal Therapeutics is a private company.
What is the current stock price of Cristal Therapeutics?
Cristal Therapeutics is a private company, so its shares have no public market price. Caplight tracks Cristal Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cristal Therapeutics worth (valuation)?
Valuation information for Cristal Therapeutics is not publicly available.
Can I buy Cristal Therapeutics stock?
Cristal Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cristal Therapeutics's last funding round?
Cristal Therapeutics's most recent funding round was Grant on July 2, 2020.
Who are the main investors in Cristal Therapeutics?
Key investors in Cristal Therapeutics include Brabantse Ontwikkelings Maatschappij, European Commission (Horizon Europe), European Commission, Thuja Capital, Brightlands Venture Partners.
Will Cristal Therapeutics IPO soon?
No public IPO plans have been announced for Cristal Therapeutics.
How can I track Cristal Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Cristal Therapeutics's shares on secondary markets.